HIPEC is considered only when a team believes surgeons can remove all or nearly all visible disease and the patient can withstand a prolonged, high-risk operation. By the end, you will know which cancers may qualify, how scans and the Peritoneal Cancer Index guide selection, and why some patients are directed toward systemic treatment instead.
Key takeaways
- CRS removes visible tumour before heated chemotherapy treats the abdominal cavity.
- HIPEC is considered only when doctors can remove peritoneal disease safely and thoroughly.
- Ask how complete tumour removal could be, not only which chemotherapy drug will be used.
- Compare expected survival benefit with recovery time, complications, and alternative treatments.
What happens during CRS plus HIPEC, and how is it different from chemotherapy through a vein?
CRS plus HIPEC is a two-stage operation: surgeons first perform cytoreductive surgery to remove visible tumour, then circulate heated chemotherapy through the abdominal cavity. The intraperitoneal chemotherapy circulation time and temperature commonly range from 60 to 120 minutes at about 41–43 °C, although drug protocols differ between cancer centres.
HIPEC exposes the abdominal lining to a high local drug concentration, targeting microscopic cells left after tumour removal. Intravenous chemotherapy travels through the bloodstream, so it can reach disease throughout the body, including areas outside the abdomen.
These treatments are not interchangeable. HIPEC does not adequately treat distant disease or replace systemic chemotherapy, which may be given before surgery, after surgery, or both according to the cancer and treatment plan.
| Treatment | How it is delivered | Main role |
|---|---|---|
| CRS plus HIPEC | Visible tumour removed, then heated chemotherapy circulated inside the abdomen once | Treat removable peritoneal disease and microscopic cells at the operation site |
| Intravenous chemotherapy | Drugs infused into a vein and carried through the bloodstream | Treat cancer throughout the body before or after surgery |
| PIPAC | Pressurised aerosol chemotherapy delivered during repeated laparoscopic procedures | Manage selected unresectable or recurrent peritoneal disease |
PIPAC is not a less invasive version of CRS plus HIPEC. It does not remove all visible tumour; specialised programmes use it during repeated procedures when complete cytoreduction is not feasible.
Which cancers may be considered for HIPEC, and when is it used in the treatment plan?
HIPEC is considered when peritoneal disease is limited enough for surgeons to remove all or nearly all visible tumour. The clearest setting is pseudomyxoma peritonei from an appendiceal mucinous tumour, although tumour grade, spread pattern, and the achievable cytoreduction affect the outlook.
| Cancer setting | How HIPEC is used | Evidence and limits |
|---|---|---|
| Pseudomyxoma peritonei | Usually CRS plus HIPEC as the main operation | One of the strongest indications in experienced centres |
| Colorectal peritoneal metastases | CRS-HIPEC for selected, fit patients with disease confined to the peritoneum | Evidence is mixed; PRODIGE 7 found no overall-survival benefit from adding short-duration oxaliplatin HIPEC to modern CRS and reported more late complications |
| Ovarian cancer | Ovarian cancer HIPEC after neoadjuvant chemotherapy during interval cytoreductive surgery | Benefit was shown in a studied stage III sequence after three chemotherapy cycles, not every ovarian operation or recurrent disease |
| Gastric cancer, peritoneal mesothelioma, or other appendiceal tumours | Considered only in carefully selected cases | Usually assessed through specialised programmes or clinical trials |
The treatment plan may use HIPEC upfront when evaluation suggests complete cytoreduction is realistic. More commonly, doctors give systemic chemotherapy first, repeat imaging and clinical assessment, then decide whether surgery remains worthwhile.
For ovarian cancer, the relevant sequence is neoadjuvant chemotherapy followed by interval cytoreductive surgery with HIPEC, after three cycles in the studied stage III population. Gastric peritoneal metastases are not an automatic indication; diffuse disease, poor treatment response, or unresectable tumour usually argues against it.
How do doctors determine whether the peritoneal disease can be removed completely?
Eligibility depends on whether surgeons can remove all or nearly all visible peritoneal tumour, not on one diagnosis or CT report. The decision combines imaging, tissue findings, tumour biology, and what surgeons see inside the abdomen.
- Contrast-enhanced CT or MRI maps deposits, organ involvement, and disease outside the peritoneum.
- Diagnostic laparoscopy can reveal small or plaque-like deposits that imaging misses.
- Biopsy and pathology review confirm the tumour type and distinguish conditions with different treatment strategies.
- Relevant tumour markers, such as CEA, CA 19-9, or CA-125, add context but do not prove resectability.
- Direct operative assessment shows whether tumour can be separated from bowel, blood vessels, and other organs safely.
The Peritoneal Cancer Index (PCI 0–39) divides the abdomen into 13 regions and records tumour distribution and size. A higher score often means a more difficult resection, but the number alone does not decide eligibility.
Extensive small-bowel involvement is a major barrier. Removing every deposit could leave too little functioning bowel, create multiple unsafe joins, or cause severe nutritional problems. CT can also underestimate low-volume or flat, plaque-like disease, so a favourable scan does not guarantee complete removal.
After cytoreductive surgery, the Completeness of Cytoreduction score records residual visible tumour. The target is complete or near-complete cytoreduction because HIPEC cannot reliably sterilise bulky tumour left behind. A consultation with Priyank Chawathe should clarify the estimated PCI, bowel involvement, and intended cytoreduction score before surgery is accepted.
Related service
Peritoneal Surface Malignancies Peritoneal Surface Malignancies Peritoneal Surface Malignancies are cancers that develop in or spread to the peritoneum, the thin lining that covers the abdominal organs and the... View service → |
When does the risk of HIPEC outweigh the likely benefit?
CRS-HIPEC is usually rejected when surgeons cannot remove all or nearly all visible disease without causing unacceptable harm. These practical HIPEC contraindications matter more than the availability of a heated chemotherapy machine:
- Disease that cannot be removed, or a low chance of complete cytoreduction
- Extensive small-bowel involvement requiring unsafe or function-limiting bowel removal
- Widespread liver, lung, bone, or other distant organ metastases
- Poor performance status or inability to manage daily activities independently
- Severe heart or lung disease
- Kidney dysfunction or inadequate bone-marrow reserve
- Poor nutrition, major weight loss, or low protein levels
- Inability to tolerate a prolonged multivisceral operation
The major surgery risks include anastomotic leak, bleeding, infection, bowel obstruction, kidney injury, blood clots, and prolonged recovery. Multiple bowel resections, extensive peritonectomy, organ dysfunction, and poor nutrition increase those risks.
HIPEC cannot reliably sterilise bulky tumour left behind, so a high Peritoneal Cancer Index or extensive small-bowel involvement may make the likely benefit too small. The team must weigh the expected Completeness of Cytoreduction against the chance of complications, intensive-care treatment, and months of recovery.
Robotic or laparoscopic assistance does not make someone eligible. Minimally invasive surgery suits only highly selected low-volume disease; extensive CRS still often requires an open operation. Disease distribution, achievable cytoreduction, overall fitness, and centre experience matter more than the instrument used.
What should you ask before accepting a recommendation for HIPEC?
Before accepting HIPEC, ask whether the team can remove nearly all visible disease and explain what happens before, during, and after surgery. A multidisciplinary tumour board should review your scans, biopsy results, tumour markers where relevant, and operative plan; CT alone can miss small or plaque-like deposits.
Ask these questions before CRS-HIPEC:
- What is my estimated Peritoneal Cancer Index, and which regions contain disease?
- What Completeness of Cytoreduction score is the operation intended to achieve: CC-0, with no visible tumour, or CC-1, with residual deposits up to 2.5 mm?
- Which organs or bowel segments might you remove, and could I need a stoma?
- Is there disease outside the peritoneum, including in the liver, lungs, bones, or distant lymph nodes?
- Does the plan include systemic chemotherapy before or after HIPEC, and what evidence supports that sequence?
- What are the alternatives if complete cytoreduction is not achievable?
| Team | Ask | Why it matters |
|---|---|---|
| Surgical oncology | What operation is planned? | Defines resection extent and achievable CC score |
| Medical oncology | When will systemic chemotherapy be given? | HIPEC does not treat disease throughout the body |
| Radiology | What do CT or MRI miss? | Small deposits may require laparoscopy |
| Pathology | Is the diagnosis and tumour grade confirmed? | Histology changes expected benefit |
| Anaesthesia | What does my operative risk assessment show? | Heart, lung, kidney, and nutrition issues affect safety |
| Critical care | What recovery and ICU support might I need? | Sets expectations after prolonged surgery |
A specialist consultation should clarify diagnosis, treatment sequence, operative risks, recovery demands, and alternatives—not present HIPEC as an automatic next step.
Frequently asked questions
What happens during CRS plus HIPEC, and how is it different from chemotherapy through a vein?
Surgeons first remove visible tumour during cytoreductive surgery. They then circulate heated chemotherapy inside the abdominal cavity for about 60 to 120 minutes, commonly at 41–43 °C. Intravenous chemotherapy travels through the bloodstream, while HIPEC delivers treatment directly into the peritoneal space after tumour removal.
Which cancers may be considered for HIPEC, and when is it used?
Doctors may consider HIPEC for selected cancers that spread across the peritoneum, including colorectal, appendiceal, ovarian, gastric, and peritoneal cancers. Its place in treatment depends on the cancer type, extent of spread, response to prior treatment, and whether surgery can remove the disease.
How do doctors determine whether peritoneal disease can be removed completely?
The team reviews contrast CT or MRI scans, operative findings, tumour distribution, involvement of the small bowel and its mesentery, and the patient’s overall fitness. They may use a peritoneal cancer index to describe disease volume and assess whether complete or near-complete cytoreduction is realistic.
When does the risk of HIPEC outweigh the likely benefit?
The balance may favour another treatment when disease cannot be removed adequately, the small bowel is extensively involved, cancer has spread beyond a treatable pattern, or major heart, lung, kidney, or nutritional problems make a long operation unsafe. Ask the team to explain the expected benefit, complications, hospital recovery, and alternatives.
What should you ask before accepting a recommendation for HIPEC?
Ask which cancer evidence supports HIPEC, whether the goal is cure or disease control, how much tumour the team expects to remove, what complications are most likely, how long recovery may take, and which alternatives remain available. Also ask about the centre’s experience with CRS plus HIPEC and the proposed chemotherapy drug and dose.
